Multidrug resistance in cancer: Its mechanism and its modulation

Drug News and Perspectives

Volumn 20, Issue 6, 2007, Pages 371-377

  Pauwels, Ernest K J ^a,b   Erba, Paula ^c   Mariani, Giuliano ^c   Gomes, Célia M F ^d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Pisa University Medical School   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; COLCHICINE; CYCLOSPORIN A; CYTOTOXIC AGENT; DAUNORUBICIN; DEXVERAPAMIL; DOXORUBICIN; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NSC 73306; PROGESTERONE; PUROMYCIN; TAMOXIFEN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOTOXICITY; DNA TRANSFER; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 36849005953     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.6.1141496     Document Type: Review

References (62)

1. Gottesman, M.M. and Ling, V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett 2006, 580: 998-1009.
2. Ling, V., Thompson, L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974, 83: 103-16.
3. Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973, 323: 466-83.
4. See, Y.P., Carlsen, S.A., Till, J.E. and Ling, V. Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta 1974, 373: 242-52.
5. Debenham, P.G., Kartner, N., Siminovitch, L., Riordan, J.R. and Ling, V. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol 1982, 2: 881-9.
6. Juliano, R.L. and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455: 152-62.
7. Riordan, J.R. and Ling, V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979, 254: 12701-5.
8. Roninson, I.B., Chin, J.E., Choi, K.G. et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1986, 83: 4538-42.
9. Ueda, K., Cornwell, M.M., Gottesman, M.M. et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986, 141: 956-62.
10. Goldstein, L.J., Galski, H., Fojo, A. et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81: 116-24.
11. Pastan, I. and, Gottesman, M. Multiple-drug resistance in human cancer. N Engl J Med 1987, 316: 1388-93.
12. Willingham, M.C., Cornwell, M.M., Cardarelli, C.O., Gottesman, M.M. and Pastan, I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effects of verapamil and other drugs. Cancer Res 1986, 46: 5941-6.
13. Cornwell, M.M., Safa, A.R., Felsted, R.L., Gottesman, M.M. and Pastan, I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A 1986, 83: 3847-50.
14. Germann, U.A., Willingham, M.C., Pastan, I. and Gottesman, M.M. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 1990, 29: 2295-303.
15. Cole, S.P., Bhardwaj, G., Gerlach, J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258: 1650-4.
16. Zaman, G.J., Versantvoort, C.H., Smit, J.J. et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993, 53: 1747-50.
17. Szakacs, G., Annereau, J.P., Lababidi, S. et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6: 129-37.
18. Dean, M., Hamon, Y. and Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001, 42: 1007-17
19. Dean, M., Rzhetsky, A. and Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11: 1156-66.
20. Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. and Gottesman, M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5: 219-34.
21. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006, 580: 2903-9.
22. Kruh, G.D. and Belinsky, M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22: 7537-52.
23. Haimeur, A., Conseil, G., Deeley, R.G. and Cole, S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004, 5: 21-53.
24. Doyle, L.A. and Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22: 7340-58.
25. Houghton, P.J., Germain, G.S., Harwood, F.C. et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004, 64: 2333-7.
26. Ross, D.D., Yang, W., Abruzzo, L.V. et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999, 91: 429-33.
27. Scheper, R.J., Broxterman, H.J., Scheffer, GL. et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein mediated multidrug resistance. Cancer Res 1993, 53: 1475-9.
28. Abolhoda, A., Wilson, A.E., Ross, H., Danenberg, P.V., Burt, M. and Scotto, K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999, 5: 3352-6.
29. Hrycyna, C.A., Ramachandra, M., Germann, U.A., Cheng, P.W., Pastan, I. and Gottesman, M.M. Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry 1999, 38: 13887-99.
30. Leslie, E.M., Deeley, R.G. and Cole, S.P. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204: 216-37.
31. Borst, P. and Elferink, R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71: 537-92.
32. Loo, T.W. and Clarke, D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 2005, 206: 173-85.
33. Baker, E.K., Johnstone, R.W., Zalcberg, J.R. and El-Osta, A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005, 24: 8061-75.
34. Malagola, M., Damiani, D., Martinelli, G. et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2007, 136: 87-95.
35. Rincon, M., Broadwater, G., Harris, L. et al. for the Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: Results of Cancer and Leukemia Group B Trial 159806. Breast Cancer Res Treat 2006, 100: 301-8.
36. Zurita, A.J., Diestra, J.E., Condom, E. et al. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 2003, 88: 879-86.
37. Yakirevich, E., Sabo, E., Naroditsky, I., Sova, Y., Lavie, O. and Resnick, M.B Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006, 100: 152-9.
38. Berger, W., Setinek, U., Hollaus, P. et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005, 131: 355-63.
39. Haber, M., Smith, J., Bordow, S.B. et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006, 24: 1546-53.
40. Modok, S., Mellor, H.R. and Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006, 6: 350-4.
41. Ford, J.M. and Hait, W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42: 155-99.
42. Liscovitch, M. and Lavie, Y. Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 2002, 5: 349-55.
43. Belpomme, D., Gauthier, S. and Pujade-Lauraine, E. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000, 11: 1471-6.
44. Hollt, V., Kouba, M., Dietel, M. and Vogt, G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992, 43: 2601-8.
45. van Zuylen, L., Nooter, K., Sparreboom, A. and Verweij, J. Development of multidrug-resistance convenors: Sense or nonsense? Invest New Drugs 2000, 18: 205-20.
46. Baer, M.R., George, S.L., Dodge, R.K. et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukaemia: Cancer and Leukaemia Group B Study 9720. Blood 2002, 100: 1224-32.
47. Wiese, M. and Pajeva, I.K. Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 2001, 8: 685-713.
48. Nobili, S., Landini, I., Giglioni, B. and Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006, 7: 861-79.
49. Le, L.H., Moore, M.J., Siu, L.L. et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005, 56: 154-60.
50. Gandhi, L., Harding, M.W., Neubauer, M. et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007, 109: 924-32.
51. Liu, Y.Y., Han, T.Y., Giuliano, A.E. and Cabot, M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001, 15: 719-30.
52. Itoh, M., Kitano, T., Watanabe, M. et al. Possible role of ceramide as an indicator of chemoresistance: Decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003, 9: 415-23.
53. Liu, Y.Y., Han, T.Y., Yu, J.Y. et al. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004, 45: 933-40.
54. Huwiler, A., Pfeilschifter, J. Altering the sphingosine-1-phosphate/ ceramide balance: A promising approach for tumor therapy. Curr Pharm Des 2006, 12: 4625-35.
55. Ludwig, J.A., Szakacs, G., Martin, S.E. et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006, 66: 4808-15.
56. van Veen, H.W. and Konings, W.N. Multidrug transporters from bacteria to man: Similarities in structure and function. Semin Cancer Biol 1997, 8: 183-91.
57. Dean, M. and Annuo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 2005, 6: 123-42.
58. Stefkova, J., Poledne, R. and Hubacek, J.A. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res 2004, 53: 235-43.
59. Dean, M. The genetics of ATP-binding cassette transporters. Methods Enzymol 2005, 400: 409-29.
60. Shi, Z., Liang, Y.J., Chen, Z.S. et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006, 5: 39-47.
61. Fracasso, P.M., Blum, K.A., Ma, M.K. et al. Phase 1 study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer 2005, 93: 46-53.
62. Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H. and Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 2007, 329: 94-102.